High expression of AXL in the majority of melanoma lymph node metastases limits treatment efficacy by promoting MM cell ability to a more aggressive mesenchymal phenotype switch from epithelial(Nyakas et al., 2022). This evidence concerns the gene AXL and Miyoshi myopathy.